Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) Operating Expenses (2016 - 2025)

Historic Operating Expenses for BioCorRx (BICX) over the last 17 years, with Q3 2025 value amounting to $2.6 million.

  • BioCorRx's Operating Expenses rose 5549.67% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 3143.08%. This contributed to the annual value of $5.1 million for FY2024, which is 3232.47% up from last year.
  • According to the latest figures from Q3 2025, BioCorRx's Operating Expenses is $2.6 million, which was up 5549.67% from $1.6 million recorded in Q2 2025.
  • BioCorRx's Operating Expenses' 5-year high stood at $2.6 million during Q3 2025, with a 5-year trough of $841650.0 in Q4 2023.
  • Its 5-year average for Operating Expenses is $1.3 million, with a median of $1.1 million in 2022.
  • In the last 5 years, BioCorRx's Operating Expenses tumbled by 5524.85% in 2021 and then skyrocketed by 7075.09% in 2024.
  • Quarter analysis of 5 years shows BioCorRx's Operating Expenses stood at $1.3 million in 2021, then decreased by 5.77% to $1.3 million in 2022, then plummeted by 33.66% to $841650.0 in 2023, then soared by 33.64% to $1.1 million in 2024, then soared by 129.46% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $1.6 million for Q2 2025, and $1.1 million during Q1 2025.